Treatment of hypothalamic cells in monolayer culture with transforming growth factor-␤1 (TGF␤1) significantly reduced both basal and cAMP-induced somatostatin messenger RNA (mRNA) levels and somatostatin secretion. This inhibitory effect was dose-and timedependent and not mediated by glial cells, as it was also observed in glial-free hypothalamic cell cultures treated with cytosine arabinonucleoside. TGF␤2 and -␤3 mimicked the actions of TGF␤1, which indicated that the three isoforms of the TGF␤ family expressed in the central nervous system displayed similar effects on the somatostatinergic neurons.
mRNA. Examination of the rate of disappearance of somatostatin mRNA by Northern blot, after inhibition of mRNA transcription with either actinomycin D (AcD) or 5,6-dichloro-1␤-ribofuranosyl benzimidazole revealed that TGF␤1 did reduce the stability of somatostatin mRNA. This effect was observed when we pretreated the cultures with TGF␤1 4 h before the addition of AcD, but not when we administered TGF␤1 simultaneously with AcD or 5,6-dichloro-1␤-ribofuranosyl benzimidazole.
Altogether these results demonstrated that the treatment of hypothalamic cells in culture with TGF␤1, TGF␤2, or TGF␤3 resulted in a decrease in somatostatin mRNA levels and somatostatin secretion. TGF␤1 reduced the steady state levels of somatostatin mRNA by inducing the synthesis of a protein (s), that appears to accelerate the degradation of the mRNA of somatostatin. Whether TGF␤1 has additional effects on the transcription of the somatostatin gene will require further study. (Endocrinology 138: 4401-4409, 1997) S OMATOSTATIN (SST) is a peptide originally isolated from the hypothalamus and shown to regulate the function of the anterior pituitary (1) . Outside the hypothalamus SST is widely distributed throughout the central and peripheral nervous system, where it acts as a neurotransmitter/ neuromodulator (1, 2) .
In the hypothalamus SST expression and secretion are regulated by a large number of classical neurotransmitters and neuropeptides, hormones, metabolic fuels, and growth factors (1, (3) (4) (5) (6) (7) (8) (9) . Furthermore, induction of SST immunoreactivity in some neuronal cell types is associated with in vivo neurodifferentiation (10) . Among growth factors, there is an increasing awareness of the importance of the transforming growth factor-␤ (TGF␤) family in the development and function of the nervous system (11) .
The TGF␤ family comprises five distinct, yet highly homologous, peptide isoforms (TGF␤1-5) (12) . TGF␤1 and TGF␤2 are 72% homologous in amino acid sequence and are interchangeable in most biological assays. TGF␤3, -4, and -5 share 64 -82% homology with TGF␤1 and -2, and parallels in their function are presently being elucidated. TGF␤s are pleiotropic peptides that can induce mitosis, differentiation, and inhibition of proliferation and function, depending upon the species, type, and maturity of the cell involved (12) . It has been recently demonstrated that at least TGF␤1-3 are expressed in the nervous system and exhibit a variety of neurotrophic actions on glial and neural cells (11) . Thus, it has been shown that TGF␤s can potentiate neuronal survival and substance P expression in neonatal dorsal root ganglia (13, 14) , regulate LHRH gene expression and secretion in the hypothalamic cell line GT1 (15) , inhibit proliferation of glial cells (16) , and modulate the expression of several growth factor receptors (17) . On the other hand, in the mature central nervous system, the expression of TGF␤1 is increased by neural injury (18, 19) , and exogenous TGF␤1 provides neuroprotection from cerebral ischemia (20) .
Taking into account that of all diencephalic areas the hypothalamus displayed the greatest density of TGF␤-inmunostained cell bodies (21), we examined here the role of TGF␤1, -␤2, and -␤3 on SST expression in hypothalamic cells in monolayer culture, assessing SST messenger RNA (mRNA) levels by Northern blot, and SST secretion by RIA. We studied the effect of TGF␤1 on basal and cAMP-induced steady state SST mRNA levels and SST release. To examine whether the inhibitory effect of TGF␤1 on SST mRNA content required de novo protein synthesis, we used two different inhibitors of protein synthesis: cycloheximide (Chx), and puromycin, and evaluated the action of TGF␤1 on SST mRNA levels in the presence of these inhibitors. Next, we studied the possible action of TGF␤1 on the degradation rate of SST mRNA, analyzing the decay rate of SST mRNA when the RNA transcription was blocked with actinomycin D (AcD) or 5, 6-dichloro-␤-ribofuranosyl benzimidazole (DRB) in the presence or absence of TGF␤1.
Materials and Methods

Fetal rat hypothalamic cell cultures
Primary monolayer cultures of hypothalamic cells were established as previously described (6) . Briefly, fetal rat hypothalamic cells (embryonic day 18) were dissociated by a mechano-enzymatic method employing a protease treatment with 2 mg/ml Dispase (Boehringer Mannheim, GmBH Biochemicals, Mannheim, Germany) and 0.05 mg/ml deoxyribonuclease (DNAse) type I (Sigma Chemical Co., St. Louis, MO), with additional mechanical shearing. Plating of 3 ϫ 10 6 hypothalamic cells per 60-mm 2 tissue culture Petri dish (Nunc A/S, Roskilde, Denmark) was carried out in ␣-modified MEM (GIBCO, Life Technologies, Gaithersburg, MD) supplemented with 10% FCS (GIBCO, Life Tecnologies), 2 mm l-glutamine (Flow Laboratories, Rockville, MD) and antibiotics at final concentrations of 100 U/ml penicillin, 100 g/ml streptomycin, and 2.5 g/ml amphotericin B. The cultures were maintained at 37 C in a humidified atmosphere of 5% CO 2 in air, and the culture medium was replaced after 4 days. After 8 days in culture, cells were washed with Earle's balanced salt solution (GIBCO) and then incubated in Krebs-Ringer bicarbonate containing 1 mg/ml BSA (Sigma) and bacitracin (Sigma) with test compounds or without them (control) .
To obtain cultures basically free of nonneuronal cells, 1.5 m cytosine arabinonucleoside (Ara-C) was added to the medium 24 h after plating and maintained in the medium during the entire culture period as shown by others (22, 23) . Culture plates were previously coated overnight with a solution of 1 mg/ml polyethylenimine in 0.15 m sodium borate buffer, pH 8.3. The plates were washed three times with sterile PBS before addition of the medium. This treatment schedule resulted in suppression of nonneuronal cell proliferation (Ͻ5% glial cells present), as assessed by antiglial fibrillary acidic protein (GFAP) staining. The immunohistochemistry for GFAP was performed as previously described (24) .
Determination of SST secretion
At the end of the experiment the medium was collected, immediately acidified to 1 n HCl, and extracted with a C-18 silica SepPak cartidge (Millipore, Bedford, MA), using standard procedures (elution of the sample from the SepPak with 80% acetonitrile in 0.1% trifluorocetic acid). The SepPak eluate was vacuum-dried and assayed for SST.
SST levels were measured by RIA as reported previously (6) .
RNA extraction
Total RNA was extracted from the cells using the single-step guanidinum-thiocyanate-phenol-chlorofom procedure (25) . Twenty micrograms of total RNA were electrophoresed on 1.5% agarose-formaldehyde gels and transferred to Nylon membranes (Hybond-Nϩ, Amersham, Arlington Heights, IL) for Northern blot analysis. Membranes were then exposed to UV light for 5 min. The blots were hybridized with an 32 P-labeled antisense SST riboprobe, transcribed in vitro by sp6 RNA polymerase from a 450-bp fragment of rat prepro-SST complementary DNA (cDNA) in pSP65 (6) . Prehybridization was carried out at 42 C for 16 h in the prehybridization solution containing 50% deionized formamide, 10% dextran sulfate, 0.1% SDS, 10ϫ Denhardt's, 0.1% pyrophosphate, 1 m NaCl, and 100 g/ml denatured salmon sperm DNA. For hybridization, 6 ϫ 10 6 cpm of the labeled RNA probe were added in 20 ml hybridization buffer, and then the membranes were incubated at 65 C for 24 h.
After hybridization, the membranes were washed twice (5 min/each) in 2ϫ SSC at 42 C, twice (30 min/each) in 2ϫ SSC, 0.5% SDS at 65 C, and twice (30 min/each) in 0.2ϫ SSC at 65 C.
Membranes were exposed to x-ray film (Hyperfilm, Amersham) with intensifying screens for 1-2 days at Ϫ80 C.
To ensure that equal amounts of RNA were loaded and transferred, membranes were washed and subsequently hybridized with a rat [␥-
32 P]ATP-labeled 18S ribosomal RNA (rRNA) oligonucleotide (24 bp), as a control probe. Membranes were prehybridized for 16 h at 50 C in a solution containing 10ϫ Denhardt's, 0.1% SDS, 2ϫ SSC, and 100 g/ml denatured salmon sperm DNA. Hybridization was performed for 24 h at 50 C in the same buffer, after the addition of 4 ϫ 10 6 cpm of the labeled probe. After hybridization, they were washed once (5 min) in 2ϫ SSC at 65 C and three times (30 min/each) in 2ϫ SSC at 40 C. Autoradiograms were developed after exposure to x-ray film for 4 -6 h at Ϫ80 C using intensifying screens.
Hybridization signals were quantitated by densitometry, using a Hirschmann (Elscript 400, Hirschrann Gersetebau, Germany) scanning densitometer. Data were expressed in arbitrary densitometric units. The results of SST mRNA levels were expressed as the ratio of SST mRNA to 18S rRNA.
Statistical analysis
Data (mean Ϯ sem) were expressed as percentage change in relation to control values (control ϭ 100). The results were evaluated using ANOVA and the least significant difference test (LSD test). P Ͻ 0.05 was taken as the criterion for significance; n ϭ number of independent experiments.
The SST mRNA decay rates were obtained by regression analysis and evaluated using a Log Rank Statistic test.
Results
TGF␤s reduce SST mRNA levels and SST secretion in hypothalamic cells
The mean levels of SST release in our hypothalamic cultures were 2 ng/plate. Figures 1 and 2 show the time course and dose-dependent effect of TGF␤1 on SST mRNA levels and SST secretion in monolayer hypothalamic cell cultures. SST mRNA content was already reduced after 4 h incubation with 5 ng/ml of TGF␤1 (30% inhibition, P Ͻ 0.01) and continued suppressed at 12 and 24 h. On the other hand, in the presence of TGF␤1 (5 ng/ml), SST secretion was not changed after 4 h, but was significantly reduced after 6 h (23% inhibition, P Ͻ 0.01), and progressively thereafter (9, 12 and 24 h). Figure 2 also demonstrates the dose-response effect of TGF␤1 for 24 h on SST secretion, with a maximum effect at 5 ng/ml (46% inhibition, P Ͻ 0.01).
To provide conclusive evidence that the effects of TGF␤1 on SST reflect direct actions on neurons, we treated hypothalamic cultures with Ara-C (1.5 m), which resulted in basically glial-free neuron cultures (22, 23) , as determined by GFAP staining (Fig. 3) . In Ara-C-treated cultures, mean levels of SST secretion in basal conditions were 25 pg/plate. Incubation with TGF␤1 for 24 h (5 ng/ml) significantly reduced basal SST mRNA levels (38% inhibition, P Ͻ 0.01) and SST secretion (57% inhibition, P Ͻ 0.01) (Fig. 4) .
We next evaluated the role of TGF␤2 and TGF␤3 on SST mRNA and SST secretion in hypothalamic cell cultures. Cells were incubated for 24 h with 1, 2, and 5 ng/ml of TGF␤1, -␤2, and -␤3, and SST mRNA content and SST secretion were measured (Figs. 5 and 6, respectively). We found that the inhibitory effect of TGF␤1 was mimicked by TGF␤2 and -␤3.
TGF␤1 reduces cAMP-induced SST mRNA levels and SST secretion
Treatment of hypothalamic cell cultures with 10 Ϫ4 m forskolin or 10 Ϫ3 m (Bu) 2 cAMP for 24 h increased SST mRNA levels by 2.5-and 3.5-fold, respectively, (P Ͻ 0.01, in both cases). This stimulatory effect was significantly reduced when cells were treated with forskolin or (Bu) 2 cAMP in the presence of TGF␤1 (5 ng/ml) ( Fig. 1 and  Fig. 7) .
On the other hand, treatment of hypothalamic cell cultures with 10 Ϫ4 m forskolin for 24 h increased SST release by 2-fold (P Ͻ 0.01). Moreover, incubation with 5 ng/ml TGF␤1 prevented the stimulatory effect of forskolin on SST release (Fig. 2) .
TGF␤1 inhibition of SST mRNA levels is blocked by Chx or puromycin
To analyze whether the reduction of SST mRNA by TGF␤1 required new protein synthesis, hypothalamic cell cultures were incubated for 4, 12, and 24 h with one of two different inhibitors of protein synthesis: cycloheximide (10 g/ml) (26, 27), or puromycin (10 g/ml) (27) , in the presence or absence of TGF ␤1 (5 ng/ml). These treatments did not affect neuronal survival as assessed by trypan blue staining (data not shown). Figure 8 shows that the decrease in SST mRNA observed after treatment with TGF␤1 was prevented when cells were incubated with Chx together with TGF␤1. The same effect was observed when cells were treated with puromycin. This clearly indicates that the action of TGF␤1 on SST mRNA content requires de novo protein synthesis.
TGF␤1 increases the degradation rate of SST mRNA
To analyze whether SST mRNA degradation was involved in SST reduction induced by TGF␤1, the decay of preexisting SST mRNA was determined by Northern blot analysis after blockade of new RNA synthesis with either AcD (5 g/ml), or DRB (25 g/ml) in the presence or absence of TGF␤1 (5 ng/ml) for varying times (1, 2, 4, 6, 12, and 24 h). The effectiveness of the concentration of AcD or DRB used in this   FIG. 4 . Prepro-SST mRNA levels (A) and SST release (B) in glial-free hypothalamic cultures (see Materials and Methods). Neurons were treated with TGF␤1 (5 ng/ml) for 24 h. SST mRNA levels were expressed as a ratio SST mRNA/18S rRNA. Results (mean Ϯ SEM) are shown as percentage change in relation to control values (n ϭ at least 3 independent experiments; **, P Ͻ 0.01).
FIG. 5.
Prepro-SST mRNA content in hypothalamic cells in monolayer culture treated with TGF␤1 (1, 2, and 5 ng/ml) (A), TGF␤2 (1, 2, and 5 ng/ml) (B), and TGF␤3 (1, 2, and 5 ng/ml) (C) for 24 h. Results were expressed as a ratio SST mRNA/18S rRNA. Data (mean Ϯ SEM) were expressed in percentage of control values (n ϭ at least 3 independent experiments; **, P Ͻ 0.01).
FIG. 6. SST release in hypothalamic cells in monolayer culture treated with TGF␤1 (1, 2, and 5 ng/ml) (A), TGF␤2 (1, 2, and 5 ng/ml) (B), and TGF␤3 (1, 2, and 5 ng/ml) (C) for 24 h. Data (mean Ϯ SEM) were expressed in percentage of control values (n ϭ at least 3 independent experiments; **, P Ͻ 0.01). study in blocking new RNA synthesis has been assessed previously (28) . Hybridization signals for SST mRNA were expressed in relation to the initial values (0 h). Plots corresponding to mean data of three independent experiments are shown in Fig. 9 , demonstrating a similar decline in SST mRNA in the presence or absence of TGF␤1.
On the other hand, the SST mRNA decay was also determined in cells that were treated with TGF␤1 alone (5 ng/ml) and compared with that observed in cells treated with AcD or DRB together with TGF␤1 (Fig. 10) . Our data showed a significantly faster decay of SST mRNA in the cells treated with TGF␤1 alone than in the presence of the transcriptional inhibitors (P Ͻ 0.05). These findings show that the effect of TGF␤1 on SST mRNA was blocked by coincubation with transcriptional inhibitors and suggest that the TGF␤1-mediated action on SST mRNA levels is dependent on the transcription of other factor(s).
Furthermore, SST mRNA content was also examined in cells that were or were not pretreated with TGF␤1 (5 ng/ml) for 4 h and then washed (time 0) and incubated for 12 h with AcD. Data were expressed in relation to the SST mRNA levels obtained at time 0. At this time the mean content of SST mRNA was significantly lower (P Ͻ 0.01) in TGF␤1-treated than in untreated cell cultures. After 12 h with AcD, we found that SST mRNA content was significantly more reduced (by 44%, P Ͻ 0.01) in cells that were pretreated with TGF␤1 than in cultures that received vehicle as pretreatment. This showed a faster degradation of this mRNA induced by TGF␤1.
Discussion
Our data demonstrate for the first time a role of TGF␤1, -␤2, and -␤3 on the regulation of SST mRNA levels and SST secretion in hypothalamic cells in culture. The administration of TGF␤1 significantly reduced SST mRNA levels. This effect was dose-dependent and was shown evident after 4 h of treatment and thereafter. Furthermore, we found that TGF␤1 also decreased SST secretion after treatments of 6 h and longer, but not after shorter incubations (4 h). This indicates that the primary effect of TGF␤1 might be on SST biosynthesis, mediated by a rapid and significant inhibition of the steady state levels of the mRNA encoding SST, followed by a reduction in SST release.
The inhibitory effect of TGF␤1 on SST mRNA and SST secretion was mimicked by the other TGF␤ isoforms expressed in the central nervous system (TGF␤2 and TGF␤3).
To provide more conclusive evidence that the inhibitory effects of TGF␤1 on SST reflected direct actions on neurons, and not effects mediated by glial cells, we treated hypothalamic cultures with Ara-C. Our data showed that TGF␤1 in these basically glial-free conditions (22, 23) also decreases basal SST mRNA levels and SST secretion.
As it is well known that SST gene transcription is regulated by cAMP through a cAMP-response element (29), we next studied the effect of TGF␤1 on the forskolin and (Bu) 2 cAMP induced SST levels. Our data showed that incubation of the hypothalamic cells with TGF␤1 for 24 h significantly reduced forskolin and (Bu) 2 cAMP-induced levels of SST mRNA content and SST release.
As with most other growth factors, the interaction between TGF␤1 and its cell surface receptors (30) constitutes the first step of TGF␤1-mediated actions. The cytoplasmic signal transduction mechanisms that follow TGF␤1 binding to its receptor are not completely understood, but multiple nuclear factors have been implicated in transducing TGF␤1 action to various TGF␤-responsive genes. It has been demonstrated that TGF␤1 may act either by inducing the synthesis of new factors (31) or by induction of posttranslational modifications of proteins or preexisting factors that bind to response elements (32) . To establish whether the ability of TGF␤1 to reduce hypothalamic SST mRNA levels depended on new protein synthesis, we examined the effect of TGF␤1 on SST mRNA content in the presence of two different inhibitors of protein synthesis:
Rates of decay of prepro-SST mRNA in the presence or absence of TGF␤1 (5 ng/ml) after inhibition of transcription with 5 g/ml AcD (A) or 25 g/ml DRB (B). RNA was isolated at the indicated times, and prepro-SST mRNA levels were determined by Northern blotting. Hybridization signals were corrected using a 18S rRNA oligonucleotide as a control probe. Data (mean Ϯ SEM of three independent experiments) were expressed as percentage change in relation to the values at time 0. The decay curves were obtained by regression analysis.
FIG. 10. Decay curve of prepro-SST mRNA in hypothalamic cells in culture treated with TGF␤1 (5 ng/ml) in the presence or absence of either 5 g/ml AcD (A) or 25 g/ml DRB (B). RNA was isolated and prepro-SST mRNA levels were analyzed as described in Fig. 9 .
cycloheximide, which traps mRNA on polysomes by inhibiting elongation of the nascent peptide; and puromycin, which removes mRNAs from polysomes (33) . Our findings showed that the administration of either cycloheximide or puromycin for 4, 12, and 24 h prevented the inhibitory action of TGF␤1 on SST mRNA levels, indicating that protein synthesis is necessary to obtain TGF␤1's full suppressive effects on SST mRNA.
The reduction of the steady state levels of SST mRNA could be due to an inhibition of transcription of the SST gene and/or to an acceleration of the degradation of the SST transcripts. To examine whether TGF␤1 acted at the posttranscriptional level by altering the stability of SST mRNA, we determined by Northern blot analysis the decay rates of SST mRNA in hypothalamic cells in culture treated for 1, 2, 4, 6, 12, and 24 h with either of two inhibitors of new RNA synthesis: AcD, or DRB, in the presence or absence of TGF␤1. We used here two transcriptional inhibitors with different modes of action: AcD, which intercalates into DNA and blocks almost all RNA synthesis, and DRB, an analog of adenosine, which selectively blocks the synthesis of heterogenous nuclear RNA (RNA polymerase II transcripts) (34, 35) .
In this study, we found that the decay rate of SST mRNA, estimated after the administration of either AcD or DRB, was not significantly different in cultures treated with TGF␤1 compared with untreated cultures. These results would suggest that TGF␤1-induced reduction of SST mRNA content is not due to degradation of this mRNA. Nevertheless, as our data demonstrated that protein synthesis is necessary to obtain the TGF␤1-inhibitory effect on SST mRNA, it could be possible that this newly synthesized protein(s) accelerated the degradation of SST mRNA, and that the synthesis of this protein was blocked by AcD or DRB. This notion was supported by our findings showing a faster rate of decay of SST mRNA in cells treated with TGF-␤1 alone compared with cells treated with a transcriptional inhibitor (DRB or AcD) together with TGF-␤1, indicating that in cells treated with TGF-␤1, SST mRNA can be stabilized by simultaneous administration of AcD or DRB. Finally, we found that when cells were pretreated with TGF␤1 4 h before the administration of AcD, they presented a faster SST mRNA degradation than cells that were not pretreated with TGF␤1.
All this together would indicate that TGF␤1 induces the synthesis of a protein(s) that appears to accelerate the SST mRNA decay. As a result, the steady state levels of SST mRNA and SST secretion are also decreased. Whether TGF␤1 has additional effects on SST gene transcription remains to be elucidated.
In conclusion, the present study clearly indicates that TGF␤s exert a marked inhibitory effect on SST mRNA levels and SST secretion in fetal hypothalamic neurons in culture and, in addition, that TGF␤s may play an important role on hypothalamic SST expression and release. Furthermore, our data suggest that in vitro assessment of neuropeptide gene expression by fetal neurons in monolayer culture can be a useful model in which to obtain further functional cues of the actions of TGF␤ isoforms at the hypothalamic level.
